Augsburg University

Idun
Theses and Graduate Projects

2019

Efficacy of a Single Dose HPV vaccine and its
Potential Outcomes in Low-Income Countries
Brooke Schramm
Augsburg University

Follow this and additional works at: https://idun.augsburg.edu/etd
Part of the Virus Diseases Commons
Recommended Citation
Schramm, Brooke, "Efficacy of a Single Dose HPV vaccine and its Potential Outcomes in Low-Income Countries" (2019). Theses and
Graduate Projects. 961.
https://idun.augsburg.edu/etd/961

This Open Access Thesis is brought to you for free and open access by Idun. It has been accepted for inclusion in Theses and Graduate Projects by an
authorized administrator of Idun. For more information, please contact bloomber@augsburg.edu.

1

Efficacy of a Single Dose HPV vaccine and its Potential Outcomes in Low-Income Countries
By
Brooke Schramm, PA-S
Advisor: Dr. Alicia Quella, PhD PA-C

Paper Submitted in Partial Fulfillment
Of the Requirements for the Degree
Of the Master of Science
Physician Assistant Studies
Augsburg University
08/20/2019

2
Table of Contents:
Abstract

3

Introduction

4

Background

5

Methods

11

Discussion

12

Conclusion

15

References

16

Appendix

18

3
Abstract
Cervical cancer is a leading worldwide cause of cancer mortality in women and
disproportionately burdens low-income countries. Human papillomavirus (HPV) has been
proven as the primary cause of genital warts, some oropharyngeal cancers, and anogenital
cancers such as cervical, vulvar, anal, and penile malignancies. HPV vaccination coupled with
regular HPV screenings are major strategies for preventing HPV infections, but with high costs
and infrastructure complexities associated with current vaccination and screening programs,
many world regions are unable to provide protection against HPV infection and its sequalae. If
unabated, cervical cancer incidence is expected to increase worldwide over the coming decades
with the largest impact on developing regions. Currently there exists a good amount of evidence
suggesting single-dose HPV vaccination may provide long-term protection against infection and
subsequent malignancies and if sufficiently effective would promote broader vaccination in the
neediest populations. Extensive literature analysis was conducted with the primary objective to
summarize and assess the evidence to date supporting a change to a single-dose HPV vaccination
schedule. Additionally, significant gaps are identified within the available research and
discussion surrounding forthcoming evidence aims to provide insight into future developments
surrounding a one-dose HPV vaccination option.
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Introduction
Cervical cancer is the third most common cancer worldwide and is also the leading cause
of cancer mortality in women of low-income countries (LICs).1 It has been estimated cervical
cancer affects more than half a million women annually, with 88% of deaths occurring in LICs, a
statistic, if unabated, is expected to increase as the population grows and lifetime risk is further
exacerbated by longer life spans.2 Cervical cancer is considered a sexually transmitted disease
resulting from human papillomavirus (HPV), most commonly HPV 16 (50%) and HPV 18 (20%)
with the remaining 30% of cases attributed to ten other carcinogenic types.3 According to the
World Health Assembly’s evidenced based interventions for preventing and controlling cervical
cancer, it was determined vaccinating females ages 9-13 against HPV as well as screening
women ages 30-49 is both cost effective and feasible.2
Vaccines have been shown as highly efficacious against high grade precursors of vulvar,
vaginal, and anal cancers suggestive of comprehensive protection against ano-genital tract
cancers. Currently three HPV vaccines are commercially available which include a bivalent
vaccine, 2vHPV (Cervarix), protecting against HPV 16 and HPV 18, a quadrivalent vaccine,
4vHPV (Gardisil), targeting HPV strains 6, 11,16 and 18, and a 9-valent HPV vaccine, 9vHPV
(Gardisil 9), covering types 6, 11, 16, 18, 31, 33, 45, 52, and lastly strain 58.4 These vaccines
were originally approved in three-dose regimens and later, after serological testing, data provided
evidence that two doses administered at least 6 months apart evoked an immune response
noninferior to the original recommended three doses. 5
Despite this progress vaccine uptake has been poor in many developing countries because
of high costs and the intensive infrastructure needed for administering consequent doses. 5
Because of these barriers, it is important to consider the possibilities if a single dose were
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deemed effective. This would reduce vaccine costs substantially and simplify vaccination
logistics enabling the implementation of HPV vaccination programs in low-income countries.
This literature review explores evidence surrounding whether or not a single dose of human
papillomavirus vaccine can prevent cervical cancer.
Background: Literature Review
HPV Vaccine History and its Current Status in Developing Countries
In the early 1980s an association between HPV and cervical cancers was reported by
Harold zur Hausen and his team and was later verified as the cause of cervical cancer after
subsequent molecular epidemiological studies.6 Research since that time has largely focused on
the prevention of cervical cancer by focusing on the prevention of HPV infection. Protection
against HPV 16 and HPV 18 strains in reduced dose schedules is of particular importance
considering these two HPV types account for around 70% of all HPV-associated cancers
worldwide.5 A major breakthrough in HPV vaccine research involved the discovery of the L1
viral capsid using recombinant technology; this capsid was found to self-assemble and has since
been used to form empty shells referred to as virus-like particles (VLPs). These VLPs are used
today when preparing the current HPV vaccines. 6,7 It has been shown that all vaccines (bivalent,
quadrivalent and 9-valent) are highly immunogenic, provide both indirect and direct protection
against HPV, and are ultimately safe. Implementation of these vaccines at a national level with at
least 50% coverage of either the 2 or 3 dose schedules has aided in lowering population level
HPV prevalence, genital warts, and cervical intraepithelial neoplasias.8
The first licensure of the HPV vaccine was of the 4vHPV vaccine in 2006 followed by
the licensure of the 2vHPV-16/18 vaccine in 2007. By the end of 2008, twenty-five percent of
high-income and upper-middle-income countries (HIC/UMIC) had implemented national HPV
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vaccination programs.8 Unfortunately, this was not the case for low and lower-middle-income
countries (LIC/LMIC) where no national introductions occurred; in fact, it was found that by
2014 only 1.1% of girls between the ages of 10-20 had been vaccinated with one or more doses
in all 84 LIC/LMICs. This is particularly alarming considering the same study stated that 70% of
cervical cancers occur in countries with no HPV vaccination program. Since then, a significant
amount of progress has been made with over 80 countries worldwide now having an HPV
vaccination program. This has in large part been a result of funding available through GAVI, the
Vaccine Alliance and with continuing aid from such an alliance, it is projected 40 million girls
will have the potential to become vaccinated by 2020. 8
The World Health Organization has recognized that routine HPV vaccination should be
included in national immunization programs and should be introduced as part of a coordinated
and comprehensive strategy which considers unique product characteristics such as price, supply
and programmatic considerations.9 This being said, it is necessary to investigate the current
evidence supporting that a one dose regimen of HPV vaccine may be enough to provide a
protective immune response. If such a single dose regimen is deemed valid, it could reduce
vaccination and administration costs, extend existing vaccine supply for a longer period and
improve uptake ultimately overcoming barriers that prohibit vaccine administration in poorer
world regions.3,8
Data from nonrandomized observational clinical trials
To determine the efficacy of a single dose HPV vaccination regimen, it is helpful to
evaluate past studies including the Costa Rica Vaccine Trial (CVT), the PATRICIA trial as well
as a multicenter prospective cohort study in India. These provide the strongest evidence to date
involving the efficacy and immunogenicity of single-dose HPV vaccination. It is critical to
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mention that each of these trial’s randomization was impaired from women missing scheduled
vaccinations for reasons unrelated to each study resulting in observational studies of different
vaccinated cohorts.
CVT, a phase III randomized control trial, was the initial study conducted that produced
evidence supporting one dose of the 2vHPV-16/18 vaccine (Cervarix), provided durable protection
against HPV infection.2 This publicly funded four-year study began in June of 2004 with 7466
consenting women who were originally randomized to receive either the Cervarix or a control
hepatitis A vaccine (Havrix, GlaxoSmothKline Biologicals). The main eligibility requirements
included being between ages 18-25, being in good health, and not being pregnant nor
breastfeeding.3 This was to be done in a 1:1 ratio at 0,1 and 6 months with the women followed
for four years annually.2 In this trial around 20% of women received less than the three dose
regimen even though the study design intended them to receive all 3 doses. Missed vaccinations
were independent of trial arm and mostly involuntary due, in large part (~35%), to pregnancy and
colposcopy referral.2,5 Infection rates were evaluated and used to determine vaccine efficacy in
this CVT study. Vaccine efficacy was found to be 80.9% (95% CI, 71.1%-87.7%) for three doses,
84.1% (95% CI, 50.2%-96.3%) for two doses and 100% for one dose (95% CI, 65.5%-100%). This
suggested that two doses of the HPV-16/18 vaccine and potentially one dose are as protective as
three doses. 10
Later, this trial’s durability was assessed involving extending the post hoc evaluation out
an additional three years to evaluate HPV vaccination seven years post vaccination in those who
received three, two and one dose.5 At year 7 they found low prevalence of HPV16 and HPV18
infection that did not have a statistically significant differences between doses. It was determined
only 1.0%, 1.3%, and 0.0% had prevalent HPV16 or HPV18 infection after receiving three-dose,
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two-dose and 1-dose, respectively. Additionally, women remained seropositive at year 7 no matter
the number of doses received and there was little difference from antibody levels when comparing
to year 4. For comparison, women who were not vaccinated had a 6.6% prevalence of HPV 16/18
infection. Furthermore, carcinogenic types of HPV that were not protected by Cervarix were
detected with similar frequency in the vaccinated group (15%) when compared to the unvaccinated
women (13%) confirming both populations had similar exposure.11 These findings suggest that
long-lived protection may be afforded even by a single dose.5
In 2004, the PATRICIA trial, a second large-scale, double-blinded randomized control
clinical trial, confirmed the CVT trial’s results by showing HPV-16/18 vaccine efficacy against a
one-time detection for three doses was 76.8% (95% CI 74.2-79.2), two doses was 73.3% (95% CI,
40.4-89.2) and one dose was 72.2% (95% CI, 13.6-92.4).3 These results strengthened CVT’s
findings with the main difference between trials being women provided cervical samples twice
annually for HPV DNA in the PATRICIA trial, instead of annually as in the CVT trial.3,7
Cumulative incidence of protection against HPV 16/18 infection hovers around 80% four years
post vaccination in both the CVT and PATRICIA trials therefore demonstrating one dose is
noninferior to three doses of HPV viral exposure. 11
In addition to the CVT and the PATRICIA study, a multicenter prospective study
conducted in India warrants attention because of its findings pertaining to immune response after
one dose of the 4vHPV vaccine Gardasil.12 In September of 2009, the International Agency for
Research on Cancer (IARC), Lyon, France, set out to evaluate efficacy of two versus three doses
of Gardasil in preventing HPV infection as well as cervical neoplasia. 4 The plan included 20,000
unmarried girls ages 10-18 years with half of the girls randomly assigned to receive either two
doses on days 1 and 180 and the other half the girls to receive three doses on days 1, 60 and 180.
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Vaccinations were administered until April of 2010, when Indian authorities suspended further
vaccinations because of unrelated events to the study. This left 17,729 girls (89% of target
population) having received at least one dose GardasilTM. By this default 4,950 (28%) received
only a single dose. When examining cumulative HPV 16 and 18 infection in all study groups
seven years later, frequencies were uniformly low. Of the 1,481 unvaccinated women, 6.2% had
infection while women vaccinated with either three, two or one dose of Gardasil TM all showed less
than 1.7% of infection within each group. One dose recipients showed only a 1.6% infection rate.4
Data provided by Immunogenicity Studies
Two non-related observational studies were conducted in Fiji and Uganda beginning in
2008. Fiji looked at 4vHPV antibody response after one, two and three doses while Uganda did
the same but for the 2vHPV vaccine. Both studies evaluated this by determining seropositivity
and antibody titers to each vaccine type.11
The Fiji ministry of Health and Medical Services received a donation of 4vHPV which
provided 200 girls ages 15-19 with vaccination of either one, two, or three doses. These girls
were evaluated in 2015 examining antibody responses to assess for differences between doses.
Results showed that 90-100% of the girls who were vaccinated in 2008 were seropositive in
2015. It was determined that girls who received one dose of the quadrivalent vaccine had
significantly lower geometric mean antibody titers (GMTs) for each of the 4 targeted types of
HPV when compared to girls who received the two or three doses, however their titers for the 4
HPV types were 5-30 folds higher than the unvaccinated group. 11,13
In Uganda blood draws were taken from 195 three-dose, 145 two-dose and 36 one-dose
recipients; after 33,39, and 33 months respectively. It was found that 99% of the women were
HPV16 and HPV18 seropositive. Immune responses were inferior in the single dose group, but it

10
is important to note that they were still 4-fold higher than natural infection. Furthermore, in the
CVT trial, effective GMT thresholds were defined at HPV16 = 124 EU/mL and HPV 18=69
EU/mL and it was found that in Ugandan girls who received one-dose 2vHPV were not lower
than this threshold. 10,14
Cost effectiveness of a one-dose HPV vaccination regimen
Informants from LMICs have reported that the key factor in their governments’ hesitancy
to include a national HPV vaccine regimen is the sustained financial commitment for the cost of
vaccine procurement and delivery. Because of this hesitancy, it is important to display the cost
effectiveness of a one-dose HPV vaccine schedule in the hopes that its implementation is given a
serious and realistic chance in the future. With the long natural history of HPV and cervical
malignancies, empirical studies have focused on evaluating efficacy and effectiveness of HPV
vaccination by relying on intermediate endpoints which include the incidence of persistent HPV
infection as well as cervical intraepithelial neoplasia (CIN). Simulating HPV disease burden in
different populations is done using mathematical models by accumulating data and projecting
long-term outcomes of decision-making interests such as cancer causes and deaths averted, or life
expectancy gained. This aids in generating evidence where data does not exist which is used to
determine health and epidemiological impacts, budget impacts and finally cost effectiveness
strategies to prevent HPV-related ailments around the world.11
According to a review on single-dose HPV vaccine by the Evaluation Consortium, one
analysis conducted in the United Kingdom and one in the United States have evaluated single-dose
HPV16 and HPV18 vaccination models in HICs and have now aimed to apply models to Uganda,
a LIC, to evaluate impact and cost-effectiveness here. It is understood in both studies that the

11
duration of protection by fewer dose HPV vaccines is critical information when determining
impact and cost-effectiveness.11
The UK analysis determined a single-dose vaccination results in substantial reduction in
cervical cancer (18-74%) and this single dose is cost-effective even when protection was only for
10 years. In the US study, the epidemiological impact of a single-dose vaccination was explored
looking at its effectiveness for 10 years, 15 years and a lifetime. The analysis projected that onedose and two-dose vaccinations protect against HPV infection and sequalae by providing
substantial reductions in population HPV 16 prevalence over time, even without lifetime
protection. Similar themes emerged from both analyses and concluded that a single-dose HPV
vaccination yields “substantial health benefits and is good value for money, even at lower vaccine
efficacy (80%) and when duration of reduced-dose protection is only 10 years.”
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Furthermore,

the cost effectiveness and impact of adding a second dose is dependent on single-dose vaccination
protection and its ability to provide higher coverage than multiple-dose regimens.11
Methods
The research topic exploring the efficacy of fewer doses of HPV vaccine surfaced as a
result of personal upcoming international travel to Costa Rica and an interest in current research
being done there. A general internet search involving studies being done within the country
provided a leading study on HPV vaccine by the Costa Rica Vaccine Trial based in the Guanacaste
province. A broad literature search was then performed to uncover information related to the
history and progress of HPV vaccination as well as cervical cancer prevalence worldwide.
Additionally, current research evaluating the efficacy of fewer than a three-dose regimen of HPV
vaccination was sought after using PubMed, PubMed Central, and ScienceDirect. The following
terms were used in the search: human papillomavirus, HPV vaccines, Costa Rica vaccines, vaccine
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efficacy, reduced dose schedules, long term protections, cervix cancer protection, low income
countries and single-dose protection. While reading through articles, additional sources were
obtained, if relevant, from in text citations as well as from references lists.
Research coalesced into key topics: HPV vaccine history, current status in developing
countries, nonrandomized observational studies, observational immunogenicity studies and cost
effectiveness with lower dose regimens. All resources used were assessed for quality and validity
and were included if recently published and peer reviewed. Initially, 22 articles were analyzed and
evaluated based upon date of publication, and relevance to the topic. Ultimately, 16 articles were
used in this literature review based upon the above criteria.
Discussion
There is no doubt that data provided in the CVT, PATRICIA, and Indian studies each
provide encouraging evidence that a single dose HPV VLP vaccine could potentially provide long
standing protection against HPV infection worldwide. All were well-organized with rigorous
enrollment and good retention to follow up and have provided the strongest evidence to justify
ongoing and additional research in this field of study.
This is not to say these trials are without weaknesses, however. The large limitation in each
of these studies was the fact they were not randomized to a reduced-dose schedule.5 Women
received one dose by default which does not offer the same protection against selection bias as a
randomized trial comparing a single dose to more doses would have. Additionally, in the CVT and
PATRICIA trials there was a small sample size in the one-dose group and infection occurrence
was used as a primary endpoint, an endpoint not accepted by cervical cancer regulators. Because
of this, policy surrounding vaccine regimens is unlikely to change as a result of these studies
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alone.2 Furthermore, these studies are heterogenous both in design and outcome assessment;
comparing immune response is challenging with the use of different assays and laboratories.
When examining the immunogenicity studies in Fiji and Uganda a prominent weakness is
the sample sizes were small which introduces potential bias in relation to individuals age and
education levels. The Ugandan study did show consistency for laboratory outcomes measure by
using enzyme-linked immunosorbent assay (ELISA) and calibrated standards equivalent to the
ones used in the CVT trial. In doing so, these results can be compared using the EU/mL standards
from ELISA, although differences between particular labs should still be considered. 11
When looking to the future of HPV vaccination policy around the world, it crucial to
identify the gaps in research, research priorities, and forthcoming evidence that will be necessary
to motivate policy change. There is no question that additional evidence is needed to determine if
a single dose of HPV vaccine provides adequate and durable protection. This evidence needs to
come from studies providing data on the immunogenicity, efficacy and effectiveness of one-dose
HPV vaccine regimens compared to two and three dose schedules that are truly randomized to
compare vaccination groups free of bias.
It is encouraging that there is a great deal of forthcoming evidence pertaining to fewer dose
HPV vaccination regimens. The CVT specifically has stated they aim to provide further long-term
data and have three complimentary component parts to do so. The first includes the extension
follow-up of the one-dose women in the CVT trial which is referred to as the “CVT Extend.” With
this extension long-term stability of antibody response will be evaluated in groups having received
one, two or three doses out to 15 years post vaccination. 2
The India study will also contribute to the data pool as they intend to extend follow-up of
participants until at least the end 2026 by working with population cancer registries that will
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generate data on HPV16/18 infections and cervical neoplasia.3 Already, around 300 women in the
single-dose group have initiated cervical cancer screening with an additional 500 women per year
being screened up to 2021.11
As stated previously there is a gap in available data involving immunogenicity, efficacy
and effectiveness of a one-dose HPV vaccine regimen compared to two and three dose schedules
that is randomized. This gap is currently being addressed by ESCUDDO, a large-scale randomized
control trial in Costa Rica, whose goal is to identify if one dose of either 2vHPV or 9vHPV vaccine
is as effective as two doses of this vaccine. One-dose will be tested for noninferiority compared to
two-doses, separately for each vaccine type.2 This will be done by evaluating 20,000 adolescent
girls ages 12-20 who are to be randomized into two stages to receive either one or two doses of
the vaccines in 2019 and followed for four years, with results available in 2023. 2,11 The ESCUDDO
trial will consider both infection rates as well as immune response. Assessing virologic endpoints
is necessary when evaluating a single dose schedule because antibody titers are inferior to twodoses and the minimum level required for protection is unknown for one-dose regimens.2
Additional trials are underway in Gambia (HANDS), and Tanzania (DoRIS) as well as an
upcoming study in Kenya (KEN-SHE). These trials are dependent on the concept of
‘immunobridging’ which is defined as, “antibody titers generated in young adolescents that are the
same or higher than generated in HPV-naive 16- to 26-year-old women, the population in which
efficacy is proven.”15 These studies will immunobridge to efficacy trials and will be important to
draw conclusions about potential protection of a single dose across different world populations
and age ranges. For example, In Tanzania, the DoRIS trial (Dose Reduction Immunobridging and
Safety Study of Two HPV Vaccines in Tanzanian Girls) intends to display whether or not a singledose of HPV vaccine can produce an immune response protective against cervical cancer. Results
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will be available in 2021 and used to immunobridge to the CVT, Indian studies and ESCUDDO
studies. 11
Conclusion
From a global perspective, the majority of HPV infection and cervical cancer mortality
occurs in the developing world where HPV vaccination and screening are significantly lacking
resulting in high morbidity and mortality rates. Substantial progress has been made with just over
80 countries, the large majority HICs, adopting HPV vaccine programs leaving an enormous need
for new strategies to help implement programs in LICs/LMICs. This comprehensive literature
review has identified a substantial amount of evidence supporting one dose HPV vaccine could
possibly be sufficient in protecting women from HPV infection and sequalae, most importantly
cervical malignancies.
There are limitations of previous studies on one-dose HPV vaccination, but current and
upcoming research with stronger data analyses may provide evidence shared around the globe
which can spark the potential for real change. The CVT Extend trial, ESCUDDO as well as several
immunobridging studies are promising efforts to demonstrate protection provided by a single dose
vaccination regimen and need critical and thorough examination when considering their validity
to promote policy change. A viable one-dose HPV vaccination schedule would substantially
reduce costs, facilitate policy and programmatic advantages over multiple dose regimens, and
ultimately widen vaccination coverage in counties with the highest burden of cervical cancers. In
conclusion, important research questions to evaluate long-term protection of a single-dose HPV
vaccine schedule and the benefits it could provide globally are of the utmost importance. Future
studies aimed at addressing these concepts will be of greatest benefit.
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